Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

Robin Kate  Kelley

Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche; Gilead Sciences; Merck (Inst)

Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Taiho Pharmaceutical (Inst)

Travel, Accommodations, Expenses - Ipsen

Bruno  Sangro

Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bayer; Bristol-Myers Squibb; BTG; H3 Biomedicine; Ipsen; Lilly; Merck; Onxeo; Roche/Genentech; Sirtex Medical

Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Lilly; Sirtex Medical

Research Funding - Bristol-Myers Squibb (Inst); Onxeo (Inst); Sirtex Medical (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Sirtex Medical

Other Relationship - Medscape; Target Pharmasolutions

William Proctor  Harris

Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Neo Therma; QED therapeutics; Zymeworks

Research Funding - Agios (Inst); ArQule (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); BTG (Inst); Exelixis (Inst); Halozyme (Inst); MedImmune (Inst); Merck (Inst)

Travel, Accommodations, Expenses - Eisai

Masafumi  Ikeda

Honoraria - Astellas Pharma; Bayer Yakuhin; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Teijin Pharma; Yakult Pharmaceutical

Consulting or Advisory Role - ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; MSD; Novartis; Ono Pharmaceutical; SERVIER; Shire; Teijin Pharma

Research Funding - ASLAN Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)

Takuji  Okusaka

Honoraria - Abbvie; AstraZeneca; Bayer; Celgene; Daiichi Sankyo; EA pharma; Eisai; Fujifilm; Lilly; Meiji Seika Kaisha; MSD; Mundipharma; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Shire; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Dainippon Sumitomo Pharma; Taiho Pharmaceutical

Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)

Travel, Accommodations, Expenses - Takara Bio

Yoon-Koo  Kang

Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Merck Serono; Novartis; Ono Pharmaceutical; Surface Oncology; Taiho Pharmaceutical; Zymeworks

Shukui  Qin

No Relationships to Disclose

Wai Meng David  Tai

No Relationships to Disclose

Ho Yeong  Lim

Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology

Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai

Thomas  Yau

Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology

Consulting or Advisory Role - Bristol-Myers Squibb

Wei-Peng  Yong

Consulting or Advisory Role - Abbvie/Genentech; Amgen; Bristol-Myers Squibb; Ipsen; Novartis

Speakers' Bureau - Eisai; Lilly; Sanofi/Aventis; Taiho Pharmaceutical

Travel, Accommodations, Expenses - Pfizer

Ann-Lii  Cheng

Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche; Lilly

Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; IQVIA; MSD; Novartis; Ono Pharmaceutical

Antonio  Gasbarrini

Consulting or Advisory Role - Abbvie; Actial; Alfasigma; Bristol-Myers Squibb; Gilead Sciences; MSD; Sanofi; Takeda

Speakers' Bureau - Abbvie; Actial; Alfasigma; Bristol-Myers Squibb; Gilead Sciences; MSD; Sanofi; Takeda

Filippo G.  De Braud

Honoraria - Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER

Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Ignyta; Incyte; Nerviano Medical Sciences; Octimet; Pierre Fabre; Roche; Sanofi; Teofarma

Speakers' Bureau - Menarini

Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)

Jordi  Bruix

Consulting or Advisory Role - Abbvie; Adaptimmune; ArQule; AstraZeneca/MedImmune; Basilea; Bayer; BioAlliance Pharma; Bristol-Myers Squibb; BTG; Eisai; Gilead Sciences; Incyte; Ipsen; Kowa; Lilly; MSD; Nerviano Medical Sciences; Novartis; Quirem Medical; Roche; Sanofi; Sirtex Medical; TERUMO

Mitesh J.  Borad

Stock and Other Ownership Interests  - AVEO; Gilead Sciences; GlaxoSmithKline

Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TD2

Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)

Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene

Philip  He

No Relationships to Disclose

Alejandra  Negro

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Masatoshi  Kudo

Honoraria - Bayer; Eisai; MSD

Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical

Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)

Ghassan K.  Abou-Alfa

Consulting or Advisory Role - Agios; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Bristol-Myers Squibb; Celgene; CytomX Therapeutics (I); Debiopharm Group; Eisai; Exelixis; Flatiron Health; Flatiron Health; Genoscience Pharma; Gilead Sciences; Ipsen; Janssen (I); LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; Pfizer (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; Silenseed (I); Sillajen; SOBI (I); Targovax (I); twoXAR; Vicus Therapeutics; Yiviva

Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); Novartis (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Polaris